ATRX and central nervous system cancer: In fact, across a variety of cancers, several recent studies have identified frequent loss-of-function mutations in ATRX, including in gliomas, pancreatic neuroendocrine tumors, melanomas, and soft tissue sarcomas (10–16) (Figure 1A).